Bosentas Tablets — Bosentan 125 mg (20 Tablets) Cipla

Bosentas 125 is indicated for adult patients in the following conditions:

• 🔹 Pulmonary Arterial Hypertension (PAH): To improve exercise tolerance and reduce the risk of clinical worsening (functional class II–IV).
• 🔹 Reduction of Digital Ulcers: In patients with systemic sclerosis and an active form of digital vascular disease.

Sales Form: 1 pack contains 20 tablets (2 blisters of 10 pieces) in a 125 mg dosage.

⚠️ INSTRUCTIONS FOR USE:

• Dosage Regimen: The 125 mg dosage is usually prescribed as a maintenance dose. The standard regimen is 1 tablet (125 mg) twice daily (morning and evening).
• Dose Transition: Typically, this dosage is started after the first 4 weeks of taking the minimum dose of 62.5 mg.
• Method of Administration: Tablets are taken orally whole, without chewing, with water. Food intake does not affect the absorption of the drug.
• Important: Do not stop treatment suddenly; discontinuation of the drug should be gradual and carried out under medical supervision.

• ⛔ Pregnancy: Strict contraindication. Bosentan causes severe fetal malformations. A monthly pregnancy test is required for women of childbearing age.
• ⛔ Liver: Initially elevated levels of liver enzymes (ALT/AST more than 3 times above the norm).
• ⛔ Interaction: Forbidden to combine with cyclosporine A and glibenclamide.
• Breastfeeding (it is recommended to stop during therapy).
• Hypersensitivity to bosentan.

Patients taking Bosentas 125 should be under medical supervision:

• 🧪 Liver Function Tests: Risk of dose-dependent increase in transaminase levels (monthly blood biochemistry control is required).
• 🩸 Anemia: Possible decrease in hemoglobin levels, especially at the beginning of treatment.
• 💧 Fluid Retention: Appearance or worsening of peripheral edema (especially ankles and feet).
• 🧠 General Symptoms: Headache, nasal congestion, hot flashes, palpitations.
• 🤢 Gastrointestinal: Heartburn, nausea, indigestion.